- Details
- Roger Li joins Ashish Kamat in a discussion on gene therapy with CG0070 (cretostimogene) and pembrolizumab in the BCG-unresponsive CIS-containing population. Roger shares the updated results from the CORE1 trial, highlighting the good efficacy results 12 months after treatment initiation. Out of the 25 patients who reached the 12-month time point, 17 had a complete response, indicating a significa...
|
- Details
- Jeremy Teoh joins Wei Shen Tan in a discussion on a multicenter randomized control trial comparing en bloc resection to standard resection for bladder tumors less than three centimeters in size. The primary outcome was the one-year recurrence rate, and secondary outcomes included progression rate and detrusor muscle sampling. The study focused on non-muscle invasive bladder cancer and recruited 27...
|
- Details
- In this conversation, Wei Shen Tan joins Ashish Kamat in discussing findings on BCG unresponsive bladder cancer patients, comparing bladder-sparing treatment and early radical cystectomy. The study they discuss shows no difference in overall or cancer-specific survival, suggesting a bladder-sparing approach may be suitable for selected patients. However, early salvage cystectomy is recommended if...
|
- Details
- In this conversation, Ashish Kamat and Roger Li discuss gene therapy in the context of non-muscle invasive bladder cancer that is unresponsive to BCG treatment. Dr. Li discusses two gene therapy treatments, Adstiladrin and CG0070, and presents promising results from a Phase 2 trial combining CG0070 with pembrolizumab. Dr. Li also discusses the BOND3 study, which is a Phase 3 monotherapy trial and...
|
- Details
- Sam Chang is joined by Patrick Soon-Shiong for a discussion on the effectiveness of N-803 for BCG unresponsive bladder cancer. They discussed the importance of an ideal profile for such an agent, which includes complete remission rate, durability of the response, and high cystectomy avoidance rate. They also highlighted the importance of the agent's safety and tolerability for urologists. The N-80...
|
- Details
- Vignesh Packiam joins Ashish Kamat to discuss a retrospective cohort study comparing the outcomes of patients with high-risk non-muscle-invasive bladder cancer (NMIBC) treated with either sequential intravesical gemcitabine and docetaxel or BCG therapy. The study included 312 patients treated at the University of Iowa tertiary care center. The primary outcome was high-grade recurrence-free surviva...
|
- Details
- Arnulf Stenzl joins Alicia Morgans to discuss the importance of proper and precise Transurethral Resection of Bladder Tumors (TURBT) as the first diagnostic step in bladder cancer treatment. He highlights the need for additional visualization techniques, such as photodynamic diagnosis or narrow-band imaging, to diagnose carcinoma in situ accurately. He also emphasizes the need to avoid piecemealin...
|
- Details
- Ashish Kamat is joined by Wei Shen Tan who presents highlights from the updated consensus on defining and managing intermediate-risk non-muscle-invasive bladder cancer (NMIBC). The intermediate-risk group is often a gray area, and there is some variation in different guidelines' definitions of intermediate-risk NMIBC. By standardizing the definition of intermediate-risk NMIBC, clinicians can bette...
|
- Details
- Wei Shen Tan joins Ashish Kamat to discuss the results of the HIVEC-II trial, a randomized controlled trial conducted across the UK that compares patients with adjuvant chemo hyperthermia with mitomycin to passive mitomycin at room temperature in the intermediate-risk non-muscle invasive bladder cancer. Adjuvant intravesical chemotherapy is the recommended standard of care for reducing the risk of...
|
- Details
- Andrea Necchi joins Alicia Morgans in a discussion on longer-term outcome data for non-muscle invasive bladder cancer patients without a carcinoma in-situ, cohort B in the KEYNOTE-057 study. The cohort B of the study focused on the patients without a CIS component and with only pTa or T1 papillary disease, high-risk disease, BCG-unresponsive disease. This is a difficult-to-treat patient population...
|
